Director
GSK
Dr. Ruchi Shah is a seasoned professional with more than 10 years of experience in the field of nucleic acid delivery, gene editing, vaccines, vaccine adjuvant development, and biologics. Her area of expertise lies in pharmaceutical development of non-viral gene therapies with a focus on formulation and analytical strategies.
Ruchi started her career as Scientist at GSK Vaccines in 2015, focusing on Self-Amplifying RNA delivery for vaccines. In the following year, she continued her path at Intellia Therapeutics in delivering CRISPR Cas9-based therapeutics with lipid nanoparticles for hepatic and extra-hepatic delivery. She also worked at Moderna Therapeutics to enable high throughput screening in their platform group. Ruchi’s career progressed rapidly at Eli Lilly and Company where she led internal and external projects to develop lipid nanoparticle formulations for pre-clinical work to deliver a diverse portfolio of RNA therapeutics. In April 2023, Ruchi joined EMD Millipore Corporation within the Targeted mRNA Delivery team as the LNP Formulation Director, heading a team for lipid design innovation and high throughput experimentation, advancing research and development in this rapidly expanding field.
In February 2025, Ruchi Shah joined GSK as the Head of US Drug Product within the Vaccines Technical and Development.
Disclosure information not submitted.
Hot Topic: Progress in mRNA LNP Understanding to Enable Refrigerated Long-Term Storage
Monday, May 5, 2025
10:00 AM - 11:00 AM ET